Chinese

COALITION LAUNCHES TO "SHUT DOWN SHEIN," PROTECT AMERICANS FROM FOREIGN INFLUENCE

Retrieved on: 
Thursday, March 23, 2023
CCP, White House, International, Communist party, SHEIN, Hoxhaism, Federal law, Clothing, Human, Woman, U.S. Customs and Border Protection, White, Radar, International law, Uyghur Forced Labor Prevention Act, UFLPA, Pharmaceutical industry, Chinese

WASHINGTON, March 23, 2023 /PRNewswire/ -- After a slew of reports regarding SHEIN's questionable business practices, human rights abuses, and ties to TikTok and the Chinese Communist Party, a new coalition today announced the launch of "Shut Down SHEIN." This campaign will educate relevant U.S. government officials and the American public to the ways in which SHEIN is alleged to be committing human rights abuses, exploiting import laws to evade billions in tariffs and making its unwitting American consumers accomplices in the process.

Key Points: 
  • The company has been accused of horrific working conditions, and their clothing has been linked to cotton picked by slaves in Xinjiang.
  • With their use of Xinjiang cotton, SHEIN is violating Federal Law, the Uyghur Forced Labor Prevention Act (UFLPA), and making American consumers unknowingly complicit.
  • Shut Down SHEIN is determined to protect American consumers and ensure a level playing field.
  • For more information on the campaign or to join the coalition, please visit: www.shutdownshein.com

Wesana Health Announces Sale of SANA-13 Assets to Lucy Scientific Discovery

Retrieved on: 
Tuesday, March 21, 2023
Asset purchase agreement, WESA, LLP, CSE, Committee, Special, MBA, Research, Sale, Chinese University of Hong Kong, WHI, Circular, US, Chinese, DSM-IV codes, Proxy, Transaction, Corporation, SEDAR, Capital, CFO, Growth, Report of the Special Committee on the Termination of the National Emergency, McCarthy, US FDA, Holding company, Car rental, Pharmaceutical industry, Lease, Security (finance), Management, Audit

The Company will also have economic exposure to the broader Lucy asset portfolio and pipeline, including a Canadian Licensed Dealer conducting research on various compounds.

Key Points: 
  • The Company will also have economic exposure to the broader Lucy asset portfolio and pipeline, including a Canadian Licensed Dealer conducting research on various compounds.
  • The Asset Purchase Agreement also contains customary non-solicitation covenants on the part of Wesana with respect to alternative transactions.
  • Accordingly, the Board has approved the Asset Purchase Agreement and recommends that Wesana shareholders vote in favour of the Transaction.
  • Eight Capital is acting as financial advisor, and Nauth LPC and McCarthy Tétrault LLP are acting as legal counsel to Wesana.

China's first personalized neoantigen-targeted cancer vaccine receives NMPA's clinical trial approval

Retrieved on: 
Friday, March 17, 2023
Survival rate, IIT, Center for Drug Evaluation and Research, DC, Clinical trial, Cancer, Chinese, B cell, Messenger, Patient, National Medical Products Administration, Immune system, 301 Hospital, CDE, Hospital, Recurrence, IND, NMPA, Tumor-associated calcium signal transducer, Safety, Pharmaceutical industry, Vaccine

This is the first personalized neoantigen vaccine & mRNA editing product approved by the NMPA to enter clinical stage.

Key Points: 
  • This is the first personalized neoantigen vaccine & mRNA editing product approved by the NMPA to enter clinical stage.
  • LK101 Injection, the first in-house developed cancer vaccine candidates by Likang, is a personalized neoantigen-targeted cancer vaccine and also a dendritic cell (DC)-based mRNA vaccine that combines advantages of both mRNA technology and DC by transducing mRNA encoding personalized tumor antigen targets based on dozens of patient-specific tumor mutations information into dendritic cells.
  • The combination of mRNA vaccine and DC vaccine provides a potential breakthrough in the field of personalized neoantigen treatment, offering an effective and safe approach for patients to fight against cancer.
  • In 2018, Likang collaborated with the Chinese PLA General Hospital to conduct an investigator-initiated clinical trial (IIT) of LK101 injection for postoperative liver cancer patients.

China's first personalized neoantigen-targeted cancer vaccine receives NMPA's clinical trial approval

Retrieved on: 
Friday, March 17, 2023
Survival rate, IIT, Center for Drug Evaluation and Research, DC, Clinical trial, Cancer, Chinese, B cell, Messenger, Patient, National Medical Products Administration, Immune system, 301 Hospital, CDE, Hospital, Recurrence, IND, NMPA, Tumor-associated calcium signal transducer, Safety, Pharmaceutical industry, Vaccine

This is the first personalized neoantigen vaccine & mRNA editing product approved by the NMPA to enter clinical stage.

Key Points: 
  • This is the first personalized neoantigen vaccine & mRNA editing product approved by the NMPA to enter clinical stage.
  • LK101 Injection, the first in-house developed cancer vaccine candidates by Likang, is a personalized neoantigen-targeted cancer vaccine and also a dendritic cell (DC)-based mRNA vaccine that combines advantages of both mRNA technology and DC by transducing mRNA encoding personalized tumor antigen targets based on dozens of patient-specific tumor mutations information into dendritic cells.
  • The combination of mRNA vaccine and DC vaccine provides a potential breakthrough in the field of personalized neoantigen treatment, offering an effective and safe approach for patients to fight against cancer.
  • In 2018, Likang collaborated with the Chinese PLA General Hospital to conduct an investigator-initiated clinical trial (IIT) of LK101 injection for postoperative liver cancer patients.

Isolation of Circulating Tumor Cells with TellDx Platform Reveals Potential Mechanism of Resistance to Immune Checkpoint Blockade in Melanoma

Retrieved on: 
Thursday, March 16, 2023
Cancer, Chinese, PD, CR, DRS, Crownsville Hospital Center, CD8, KEAP1, Biomarker, Doctor of Pharmacy, CTC, ICB, Patient, Toxicity, Metastasis, NRF2, Melanoma, Massachusetts General Hospital, NPJ, Harvard Medical School, RNA, Doctor of Philosophy, DOI, Neoplasm, HIV disease progression rates, Vaccine, Medical imaging

BEVERLY, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection of cancer through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx CTC System, announces publication of data from the scientific founders that reveal downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade (ICB). The paper, titled “Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade,” was published on March 02, 2023, in NPJ Precision Oncology (DOI 10.1038/s41698-023-00362-3).

Key Points: 
  • The paper, titled “Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade,” was published on March 02, 2023, in NPJ Precision Oncology (DOI 10.1038/s41698-023-00362-3 ).
  • While ICB has significantly improved clinical outcomes in melanoma, a subset of patients do not respond or develop resistance over time.
  • “These exciting data demonstrate that isolation of CTCs from melanoma patients with the TellDx platform and subsequent single cell RNA sequencing can reveal pathways of response and resistance to ICB.
  • Overall, these data provide valuable insights into the mechanisms behind melanoma resistance to immune checkpoint blockade therapy and highlight the potential of monitoring CTCs to improve outcomes of patients with cancer.

Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results, New Business Strategy Focused on Precision Oncology

Retrieved on: 
Tuesday, March 14, 2023
ACT, AstraZeneca, Cancer, Acquisition, United Kingdom, Workforce, Medicine, Chairperson, Genomics, Chinese University of Hong Kong, Chinese, Patient, Nature, Investment, EBITDA, COVID-19, FDA, Communication, Growth, Coronavirus Scientific Advisory Board, Social responsibility, Cryptocurrency, Pharmaceutical industry, Medical imaging, Vaccine, Renewable energy, Video game, Insurance, Bank, Artisan

-- Cash and other short-term assets of US$242.1 million as of December 31, 2022

Key Points: 
  • -- Cash and other short-term assets of US$242.1 million as of December 31, 2022
    -- Embarked on a new business strategy focused on precision oncology, as the Company exits the COVID-19 testing business.
  • Furthermore, I am immensely optimistic with our new business strategy in precision oncology.
  • Prenetics is focusing its business strategy to genomics and precision oncology, and is dedicated to transforming patients' care through advanced genomic and molecular technologies.
  • -- Adjusted EBITDA was US$12.1 million for the fourth quarter 2022 compared to US$(5.9) million for the fourth quarter 2021.

Feature Film 'Tell It Like a Woman' Hosts Red Carpet And Screening at Los Angeles Italia Film Festival Ahead of Academy Award Nomination for Best Original Song

Retrieved on: 
Wednesday, March 8, 2023
Chinese, International, Grauman's Chinese Theatre, Tell It Like a Woman, Woman, ILBE, Q&A, Applause, Film industry

LOS ANGELES, CA, Mar 8, 2023 - (ACN Newswire) - International movie star Jacqueline Fernandez arrived at the 18th edition of the Los Angeles Italia Film, Fashion, and Art Festival event accompanied by Hollywood Producer Andrea Iervolino.

Key Points: 
  • LOS ANGELES, CA, Mar 8, 2023 - (ACN Newswire) - International movie star Jacqueline Fernandez arrived at the 18th edition of the Los Angeles Italia Film, Fashion, and Art Festival event accompanied by Hollywood Producer Andrea Iervolino.
  • The event featured a red carpet premiere, screening and Q&A for the film Tell It Like A Woman.
  • The film is currently nominated for an Academy Award Nomination for Best Original Song for the song "Applause" written by Diane Warren and performed by Sofia Carson.
  • During the Los Angeles Italia Festival awards ceremony, which was held at the Chinese Theater in Los Angeles, Andrea Iervolino was honored with the Los Angeles Italia Excellence Award and Jacqueline Fernandez was honored with the Los Angeles Italia Humanitarian Award.

Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Tuesday, March 14, 2023
ACT, AstraZeneca, Cancer, Acquisition, United Kingdom, Workforce, Medicine, Chairperson, Depreciation, Genomics, Chinese University of Hong Kong, Chinese, Nature, Investment, EBITDA, COVID-19, FDA, Communication, Growth, Coronavirus Scientific Advisory Board, Social responsibility, Cryptocurrency, Bank, Pharmaceutical industry, Medical imaging, Vaccine, Renewable energy, Video game, Insurance, Artisan

Revenue was US$52.3 million for the fourth quarter 2022 compared to US$64.7 million for the fourth quarter 2021, a decrease of 19.2% year-over-year.

Key Points: 
  • Revenue was US$52.3 million for the fourth quarter 2022 compared to US$64.7 million for the fourth quarter 2021, a decrease of 19.2% year-over-year.
  • Gross margin was 51.6% for the fourth quarter 2022 compared to 36.7% for the fourth quarter 2021.
  • Profit from operations was US$4.6 million for the fourth quarter 2022 compared to loss from operations of US$30.8 million for the fourth quarter 2021.
  • Adjusted EBITDA3 was US$12.1 million for the fourth quarter 2022 compared to US$(5.9) million for the fourth quarter 2021.

YuanTech Solar Delivers its First Shipment to Brazil

Retrieved on: 
Tuesday, March 14, 2023
Chinese, Maintenance, Certification, PERC, Partnership, INMETRO, Renewable energy

SHANGHAI, March 14, 2023 /PRNewswire/ -- YuanTech Solar, a new PV manufacturer in China, announced its first shipment to the Brazilian market on March 10, after obtaining the INMETRO certification in Brazil earlier this year.

Key Points: 
  • SHANGHAI, March 14, 2023 /PRNewswire/ -- YuanTech Solar, a new PV manufacturer in China, announced its first shipment to the Brazilian market on March 10, after obtaining the INMETRO certification in Brazil earlier this year.
  • YuanTech Solar is steadily expanding its global business footprint as its products are widely recognized by customers worldwide.
  • The product being marketed in Brazil is 550W PERC 72-cell module, which is also one of the most popular products on the market today.
  • Mr. Xie Jian, Founder and CEO of YuanTech Solar, said that cross-regional cooperation is the test of the service quality of YuanTech Solar's overseas sales team.

Generative AI Market to Reach $126.5 Billion, Globally, by 2031 at 32% CAGR: Allied Market Research

Retrieved on: 
Friday, March 10, 2023
Variational autoencoder, Hoxhaism, Workforce, Software, Media, Growth, IDEA, PDF, Identity theft, BFSI, Transport, COVID-19, Machine learning, Table, Telecom, VAE, Generative adversarial network, AI, News, Communist party, Component, National Diffusion Network, Ecosystem, Deep learning, Environment, Medical device, Video game, Health care, Chinese, Transformer

PORTLAND, Ore., March 10, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Generative AI Market by Component (Software, Services), by Technology (Generative Adversarial Networks (GANs), Transformer, Variational Autoencoder (VAE), Diffusion Networks), by End User (Media and Entertainment, BFSI, IT and Telecom, Healthcare, Automotive and Transportation, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031"According to the report, the global generative AI industry was valued at $8.15 billion in 2021 and is estimated to generate $126.5 billion by 2031, witnessing a CAGR of 32% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chain, regional landscape, and competitive scenario.

Key Points: 
  • However, generative AI has security issues as some models can be used fraudulently, leading to increased identity theft and high implementation cost.
  • The outbreak of the COVID-19 pandemic had a positive impact on the generative AI market.
  • This is owing to the surge in the use of generative AI to create realistic virtual & augmented reality experiences.
  • Also, many new companies in the region are being formed to develop & commercialize AI technology, including generative AI.